




Funding Provisions of PMPs

Research Current Through May 2016.

This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points of view or opinions in this document are those of the author and do not necessarily represent the official position or policies of the Office of National Drug Control Policy or the United States of Government.

© 2016 Research is current as of May 2016. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites. Please contact Sherry Green at 703-836-6100 or sgreen@namsdl.org with any additional updates or information that may be relevant to this document. Headquarters Office: The National Alliance for Model State Drug Laws, 100 ½ E. Main Street, Suite C, Manchester, Iowa 52057.

Funding Provisions of PMPs¹



¹This information is derived from the state PMP statutes and does not include any information that might be found in the state licensing or other statutes. ²Ohio allows licensing and other fees from pharmacists, pharmacy interns, and certain distributors of dangerous drugs, but specifically prohibits the imposition of a fee on prescribers. ³The Texas provision becomes effective September 1, 2016. ⁴Vermont specifically excludes licensing and other fees from practitioners, but does partially fund the PMP through fees assessed to pharmaceutical manufacturers. ⁵The Alaska provision goes into effect on September 1, 2016.